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Sixtnn txdienk with severe hypertension were treakd for I gear 
with extended ret- nikdipine, during whkh time serial changes 
O.odol) at I year. AtIer 6 months, kn ventricular ma% k&xws 
signitieantty reduee4 by 19% fmm 121 + 8 to 94 f 7 $m’ and this 
reduetk” w sustsined a, t year. Septsl and posterior wall 
thkknfs were reduced from 13.4 = 0.1 to 11.2 2 0.84 mm and 
from 12.8 + 0.1 to 10.0 2 0.03 mm ,p < O.OOI~, rezpectkely. 
The prevalence of kh venlricukr hyperfrnphy decreawd horn 
43% to 29%. Len veotrictdw fmetiinat shorte.dng increased 
frcm, 34 t 2% to 41 * 3% (9 < 0.09) and the relation between 
fractional rhortming and eed.s~stolie stress did ll~t change. Over 
the )ear of sustained blood pressure rchrctkn, the peak wlority 
of early tilling inereawJ fmm 57 * 3 to 63 f 4 cmlr tp = 0.07). 
pali velocity cf kk titling did not change awl tht ratio of kk to 
eartv malt kn ventrkukr lilline wkeitv simtfaettv decreased 
(p 2 b.05). Plaina atria! natritlmtk &b&k kvd;. mar!iedly 
elevated at entry, decreased frwn 70 * IS to 41 C 8 pelml at 
Left ventricular hypertrophy. a common finding in severe 
arterial hypenensioi. is in independent and paverful pre- 
dictor of future cardiovascular morbidity and mortality in 
patients with arterial hypertension (I-5). Antihypertensive 
therapy reduces the mortality rate associated with severe 
hypenension (6). but reversal oftarget organ disease has not 
been characterized in severe hypertension. A recently avail- 
able extended release formulation of nifedipine with phar- 
macokinetic properties suitable for once daily administration 
effectively lowers blood pressure in a sustained fashion in 
patients with severe hypertension (71. The purpose of this 
study was to evaluate the effects of this therapy. either I) 
monotherapy or in combination with a thiaride diuretic drug. 
on left ventricular structure and fwclior, and to characterize 
the associated neurwndocrine response to a sustained re- 
duction in blood pressure in patients with severe hyperten- 
bion. 
Methods 
Patiatt sekelion. Patients were identified in the enw- 
gency room on the basis of a screening seated diastoiic blood 
pressure h I20 mm Hg. They were eligible for participation if 
after 30 min of rest in a quiet room. the average seated 
dinstolic blood pressure was =:?O mm Hg 08 three determi- 
nalirrnr over a period of 3 min. Aiter history aad physical 
examination. subjects were excluded for suspected second- 
ary hypertension or hypertensive emergencies (that is. acute 
myocardial infarction. unstable angina. dissecting aneurysm. 
pulmonary edema. cerebrovascular accident. subarachnoid 
hemorrhage or hypertensive encephalopathyl. The protocol 
was approved by the Institutional Review Board of Mount 
Sinai Medical Center and informed written consent was 
obtaiwd from all subjecti. 
Echocardiographii and Doppler measurentents. Serial 
echocardiograms were obtained with a commercially avail- 
able ultrasound system (Ultramar 4. Advanced Technology 
Labaratones) usmg a 3 MHz transducer for M-made. two- 
dimensional and pulsed Doppler recordings. Two-dimen- 
sionally guided M-mode echocardiography ofthe left vent, i 
de was performed immediately below the mitral wlve 
leaflets at the chordal level. Two-dimensionally guided 
puked Doppler interrogation of left vcnlricular inflow WBF 
done from the apical two or four chamber view. Left 
ventncular inflow was interrogated between the mitral anu- 
Ius and the leaflet tips. Recordings of left ventricular inflow 
were made where maximal velocity of early filling was 
obtained. Pulsed Doppler recordings of aortic outflow were 
obtained to calculate cardiac outout. All Doppler and 
M-mode recordings were made on videotape at lti mm/s. 
Echocardiographic and Doppler analysis. All studies were 
analyzed from vtdeotape using a commercially available 
dieitizcr Wova MicroSonics 10 440, Advanced Technoloay 
Laboratories). M-mode variabies were analyzed accord& 
to the American Society of Echocardiography convention 18) 
and included IeR ventricular end-diastolic and end-systolic 
diameters rind septal and posterior wall thickness. Left 
ventricular mass was calculated by using an anatomically 
validated recrcssion eauation that corrects left ventricular _ . 
mass estimates obtained from American Society of Echocar- 
diography measurements (9). The 97th percentile (al34 g/m’ 
for men and 21 IO g/m’ fur women) was used as the cut-off 
value Sor left ventricular !typertrophy (101. End-systolic 
stress was calculated accortiing to previously described 
methods (1 I). Random variability of the echocardiographic 
measurements was reduced by using previously validated 
methods 112) and by viewing simultaneously acquired two- 
dimensional images to as& proper alignmknt of the 
M-mode cursor. At least five spectral tracings of the mitral 
inflow were digitized and averaged to obtain peak velocity of 
early and late diastolic filling and the ratio of late to early 
diastolic flow velocity (13). Cardiac output was calctlated 
from the product of stroke volume (obtained from pulsed 
Doppler recordings of the aortic outflow) and heart rate t14). 
At least five spectral tracings were digitized to obtain the 
flow velocity integral. Studies were analyzed by an observer 
“naware of the study phase and treatment. 
Ekcttwardioerams. Throuehout the course of the studv. 
I2 lead electroc~rdiogmms (E&s) were serially obtain&l. 
The ECG was scored accordine to the Romhilt-Estes v~tem 
115). the Cornell system (16) and the criteria established in 
the National Health and Nutrition: Examination Smwy I 
(17). The ECG was analyzed by a reader unaware of the 
treatment or study phase. 
Initial treatment. After initial studies. treatment with 
nifcdipine (IO tng) was given by having the patient bite the 
capsule and swallow the content (IS). Blood messure was 
‘&&xed at 10 min intervals with’ an a&m& device 
(Infrasonde model D4CUlO. Puritan-Bennett). Echocardio- 
graphic and Doppler studies were repeated 60 min after the 
dose of nifedipine. 
Lang-term therapy. After initial treatment, patients were 
placod on monotherapy with an extended release prepara- 
lion of nifedipine lnifedipine gastrointestinal therapeutic 
system). Because extended release nifedipine provides rela- 
tively constant release of the drug over 24 h (19). patients 
were instructed to take the medication at a convenient but 
consistent ime of day to ensure compliance. The initial dose 
of 30 mg once daily was titrated over a period of I4 to 40 
days (mean 28) to a maximal dose of 150 mg to achieve a 
diastolic blood pressure r95 mm Hg(end-tittxtion) 14,024 h 
after the previous dose. If blood pressure remained above 
this level with I50 mg of extended release nifedipine or if the 
patient could not tolerate 150 mg of nifedipine but still had a 
diastolic blood pressure ~95 mm Hg, chlorthalidone 
(50 mglday) was added to the regimen. 
plasma hormones. Before initial treatment with nife- 
dipine. each subject was placed in the supine position. an 
antecubital vein was cannulated and after 30 min. blood 
samples were drawn for plasma renin activity. norepineph- 
rine. epinephrine and atrial natriuretic peptide determina- 
tions. Plasma win activity was measured by radioimmuno- 
assay and catecholamines were measured by high pressure 
liquid chraratography. Atrial natriuretic peptide was mea- 
sured from extracted plasma by radioimmunoassay. as pre- 
viously described (20). These studies were repeated after 2. 
6 and I2 months of sustained blood pressure reduction. 
Statistical analysis. Results are expressed as mean valttes 
t SE. Data were analyzed with SAS statiStical programs. 
Analysis of variance was used to determine if there was a 
treatment effect. Student’s paired I test was used to test the 
difference between mean values and chi-square analysis was 
used to test distributions. Linear regression analysis was 
used to determine whether correlations existed between 
variables. Analysis of covariance was used to detertut if 
there was any diUerence between the slope and intercept of 
the relation between fractional shortening and end-systolic 
stress at various phases of the study. 
Patient charaeterislics (Table I). The study group com- 
prised middle-aged patients with an ethnic mix that reflects 
the inner city in which the study was conducted. There was 
mild obesity and normal renal function as reflected by serum 
creatinine levels. Pretreatment supine diastolic blood pres- 
sure was severely elevated @I20 mm HgJ in all patients. 
Four patients were not taking any medicatiun at study entry. 
2 reported taking a short-acting calcium channel blocker 
within the preceding week and lOreported taking medication 
within I day of studv entry Ian adrenercic blocker in 3. an 
angiotensin&tveni~g eniyme inhibitor in I and vamw 
combinations of a diuretic drug with an angiotensin- 
converting enzyme inhibitor. an adrenergic blocker or a 
short-actinp: calcium channel blocker in 61. 
Simen ,&enrs were exclud~dfmm the .srudy hefin- CL? 
Eight patients were excluded because diastolic blood pressure 
decreased to < I20 mm Hg after 30 min of setting. sir because 
of evolving myocardial infarction. evolving cerehrovawlar 
accident &chest pain, one patient because of a surpectcd and 
subsequently proved and cured pheochmmocytoma and one 
because of suspected clonidiie withdrawal. 
FVetreatmenl mt&uwments ITabler 2 aed 31. At entrv to 
the study, left ventricular hypertrophy was present in IO 
(6381 of the I6 tntients. as demonstrated bv maderatelv 
increased septal ‘and posterior wall thickness (Table 2;. 
Relative wall thickness and systolic w.iI sfresc were cle- 
vated and fractional shortening was maintamed in the normal 
rsnge. The ECG estimates of left ventricular hypcrtrophy 
sueksted a hb?h txevalence of bvwrtrophv. Mean &ma 
re& activity &within the nor& m&and all <;hjects 
had either a low or a normal level (Table 3). ‘Mean i?la?ma 
norepinephtine and plasma epinephrinc levels ww &WI. 
Alrial natriuretic peptide concentration (see Fig. 4) w11 
significantly elevated above our previously determined nw 
mal range (20). 
Effect nf long-term treatment on hhmd p,wwre and hext 
rate (Fig. II. At the end of 2 mcmth5. II (6W) of the Ih 
patients had effective control of hlwd pre~wre on mono- 
therapy unh w.tend,-d r~lw.c mf?dipine. hut 5 l31’7r) rc- 
qntred additwn of chlorthalidnne. Rlnod preswre in patient% 
who were monitored I4 to IR h after their preview do<e wac 
Gmilnr to that in patients monitored IR to 24 h after their last 
dew t I53 : I l/R9 - I “1. I?0 L IZi9Il~ 2 mm Hg. p = NS). 
Rlood precrure WP effectively cnntrolled for I year. The 
median dorc of extendrd r&we nifedimne was I20 me. Of 
the five patients who reqmred chlwthalidone. four were 
recewinp I?0 mp of extrndcd XIPRIC nifedipine and one 
patient was receiving ‘Xl mp. Heart mte was Rt + 5 beatsimin 
ot rnrry nnd did nnt chance sienificantlv over the coune of 
fhc Wdy. 
E&cl of treatment on Ml ventricular mass (Table 2, Fig. 
2). By 6 months. left ventricular mars index decreased 
significantly by IY% and this effect was sustained over I 
year. Left ventricular mass reuession was accounted for by 
a significanl 22% reduction in-posterior w II thickness (p 2 
O.WIl and a 16% reduction in interventricular serxal Ihick- 
nest (p < O.WI I. There was no change in the left &Uicular 
internal dimemion. A similar decrease in left ventriculilr 
mass war observed in patients on extended release ni- 
fedipine monotherapy and in lhose who required 3 diurclic 
drug l-24.6 r 9and -19 c 4@n’. rerpectively. p > 0.5). At 
I year. wall thickness had normahzed and the prevalence of 
Figure 2. Effecl of ireatmcnl un lefl ventriculilr (LV) mass index in 
Ih patients. The prevalence of left wn!rxular hypermphy was 
reduced from 63% 10 25% after b monlh, of ,ream,en, ,ree text for 
detail\) 
Figure J. individual values for end-ryaolic slress und corrcrfond- 
ing fractixud rharieninp before ropm clnlal and after Mused 
circlea) I year of therapy. The predicted regression line for the 
prerreatmcnl r&&on between end-syrlic srrcss and fractional 
shortening with Ihc 95% confidence interval for the predicted line 
lnot !he 95% confidence interval for individual palientsl in also 
shown. The reladon did nor change after left ventricular mass 
regression and treatment with extended release nifedipine. suggest- 
ing thl intrinric left vrntncular eontractilhy was not abered. 
whereas none of the patients with a <2S mm Hg decrease in 
systolic blued pressure had a 22s g/m’ decrease in left 
ventricular mass @hi-square = 5.1. p = 0.02). Finally. 
although blood pressure at study entry did not correlate with 
the degree of left ventricular mass regression. subjects with 
a higher end-systolic stress at entry tended to have a greater 
decrease in left venwicular mass (r = 0.46. p = 0.07). 
Ow rhe (vwx of rhr gear. there WBS a 28% decrease in 
Ihe Romhill-Estes point score (p = 0.05) and a 14% decrease 
Ip < 0.02) in left ventricular mass according lo the quanli- 
lstive ECG criteria derived from the National Health and 
Nutrition Examination Survey I (17). There was no signifi- 
cant change in the Cornell voltage criteria (R have in lead 
aVL plus S wave in lead V, [R,,“, + S,J 1161. At study 
entry. there was a significant corre!ation (r = 0.64, p < 0.01) 
between echocardiagraphic estimates of le!l venuicular 
mass and Ihe Romhiit-Estes ECG poinl score and a signili- 
canl correlalior: (r = 0.54. P < O.OS) betwex~ the decrease in 
echocardiographic estimates of left ventricular mass and the 
decrease in the Romhilt-Estes point score. In conlrart. no 
relation was detected at entry between echocardiographic 
estimates of left ventricular mass and either the &&II 
voltage criteria or the National Health and Nutrilion Exam. 
ination Survey I KG estimates of left ventricular mass or 
between changes in these ECG criteria and changes in 
echucardio$raphic estimates of left ventricular mass. 
Effwl 01 treatmenl on kN vedriculer function and hor- 
mones (Table 3, Fig. 3 and 4). Fraclional shortening was 
significantly higher after I year. Funhemwe. the relation 
between fracMmal shortening and end-systolic press did no! 
-- 
Figure 4. E&cl of treatment 08 plavna atnal natrwret~ pepode 
tANPI in 16 patients. This peplide. whach wflects cardiac filling 
preswrer. was markedly clevaled at stud, C”“). but reurncd 
toward normal levels with treatment. 
change over the course of treatment IFig. 31. Thi, lindmg 
suggests that left ventricular mass repreyyion and treatmwt 
with extended release nifcdipine did not advenely affect 
intrinsic left ventricular contractility. Cardw output did not 
change from that at study entry. 
To obviate the confoanding effecta on left ventricular 
filling that are introduced by markedly slevated afterload 
(21). left ventricular filling variables obtained at I YCLI- were 
compared with those at end-titration (goal blood preswrc). 
when bled pressure had been lowered and stabilized. Over 
the year. there was a trend toward an increax in the velocity 
of early filling (57 + 3 vs. 63 2 4 cmlr. p = 0.07~. a trend 
toward a decrease in late diastolic filling IS? z 4 w. 78 L 
4 cmlsl. and a significant decrease in the ratio of lk~te to earl% 
peak velocity of left ventricular filling t I .5! 2 0. I bb. I ?X c 
6.07. p < 0.051. There was a trend towrd a relation betnccn 
left ventricular mass regression and a decrease III the rotio of 
Iale to early peak velocity of left ventriculx tilling lr = 0.12. 
p = 0.07). There was no :elauon between change m heart 
tae and change I” any of the ~imdoIc\ of icft ~eotr~~~lilr 
filling. 
X2 b\. 503 2 I?? pglml). *herea\ there was a trend toward 
a decrea?c m those on susrained nifcdapmc monotherilpy 
((27 z i? v\. 439 2 56 pun,,,. 
Side effects. Trace psri?heral edema aa\ precent m 
newly 50% of wbjects. but this did not lcad to wthdmaal 
from rherap). Gingival hypaplasia was found m two pa- 
lienI\. Wnhdrawal from treatment was not required m any 
subject bccauir of side effecrs. 
Discussion 
Principal findings. Thip is the first blody using calcium 
channsl blockade to demonstrate thol sustained II year1 
coorrol of severe hypertension is aswiated wth regression 
of left ventrudar mass. Mass regression occurred because 
ofa decrexe in wall thickneu mtothe normal range aithout 
a change m left ventricular chamber dimensions. Left veo- 
tricular mas, regressioo ws confirmed by both echocardio- 
graphic and ECC criteria. The pre~&~e of echocard!“. 
graphically determined left ventricula hgpertrophy \\a< 
reduced from 63% to 25% after I year of treatment. Whereas 
both the Romhilt-Estrs ECG point score (15) and the qua”- 
t~tatwe KG estimates of left ventricular mass developed 
from the National Health and Nutrition Examination Survey 
I I171 demonaated a significant decrease. onl) the former 
correlated utth echocardiograph? estimates of left ventric- 
ular mow regression. To obtain ventricular mass regresrion. 
blood orc’\,urc ,+as effectwelv controlled by extended re- 
lea% nifedipine for I year in Ii t6Y%) of the i6 pa&r&: the 
remamine 5 131%) reauired the additiun ofchlonhalidone. In 
C~OIIP% )o the only other prevtous report (!2) of regres:;ion 
of left wotricular otw m severe hypertension. 89% required 
combtnation therapy with cilazapril ta converting enzyme 
mhibitorl ;tnd hydrochlorothiaride am the blood pressure of 
only I I? could be controlled with monotherapy. 
Atrial natriuretic peptide wils markcdlv reduced ot 2 
months and this was teen in subjects on c;,snded rclca\e 
nifedipine monotherapy (65 r I8 vs. Jh 5 I I pgimll and in 
those who required chlorthalidone IX6 t 27 w 41 2 
IO p&nll. This effect wa\ wtoined at I year IFig. 4). The 
decrease in alrial niltriurrtic pcpttde wa* not related to the 
change in either left *entricular ma\ or the mtiu of liw to 
earlv peak velocw of left ventricular i&w. 
Lklerminants of IeR rentrieular mass regresston. The de- 
temGnimts of left ventricular ntoss regression in patients 
treated wi’i antihypcrtencive therapy are not fit nly estab- 
li*hed. The class of antihypertensive agent used for treat- 
ment. the drgree of blood pressure reduction and the cause 
of the h!pcrtrophy may all play a role. In additton. the 
character~\ticr of the study patient, most also be considered. 
Thi, rlady was conducted in predominantly mtddle-aged 
bksh .md Hi,pnnic patients with low to normal plasma renin 
acti\ ity. Therefore. the vslidity ofextrapolating;hese results 
to all demographic groups with systemic arterial hyperten- 
*ion i\ nui ?et pro&. 
dvm I year. there *a\ oo l igoiiis.mt chagc m cithcr P&r&in this study treated wi!n diuretic drugs experi- 
plasma renin activity or wecholsmme level\ ITable 31. cnced left ventricular mars regression. The ability ofdiuretlc 
However. as expected. thow po,,cot\ who required chlor- agents it, monotherapy to reduce left ventricular mas is 
thalidone had 11 trend touard an mcrpiw m plaw~ renir controwwal. Although thir *tudy cannot shed light on this 
activity 12.1 z 0.9 ~5. 5.6 2 2.8 ng ;mgiotcnrinlml pfr bl. question. it demonstrnte~ that thiazide diuretic drugs do not 
whereas those on extcndcd rcleax olfcdwme monotherwy blunt the effect of extended nifedapice therapy on left vcn- 
hild no change, 1.3 I 0.) vs. I.6 + 0 4 ng img~,,cndml per triculhr marr regression. 
h). Sirmlarly. patients lahing chlorthahdone had a treno over Grcn the magnitude of the dccreae in blood presure. 
I year toward an increac IS pla\ma norcpmephrinr 074 2 ue were uprised by the absence of a direct linear relation 
lratrurctic peptide concentration (reflecting filling pressures) 
WOIL’ stable over the period of increased velocity of early 
hlling. improved intrinsic left ventricular relax&m may 
have accounted for the increased velocily of early filling. 
The trend toward a relation between left ventricular mass 
regrarion and a reduced ratio of late Lo early filling is in 
wcord with recent studies Q-31 b wth calcium channel and 
beta-adrenrgic blockers. in which left ventricular mass 
rcgreGwi as a result of decreased wall thickness was 
accompanied by apparently improved left ventricular filling. 
However. because there mav be direct e&cts of nifedioine 
on left ventricular diastolic properties in the hypertrophic 
(nonobstrucive) heart (32). it is possible that the apparer 
improvement in left ventricular filling was simply a drug 
cnect. 
M~r.rrlel~ollupcn rurio. Another potentially deleterious 
effect of left ventricular mass regression is a possible reduc- 
tion in muscle/collagen ratio. leadins to an overall stitTer 
ventricle. This is the case early der aortic valve replace- 
ment. where regression of hypcrtrophied left ventricular 
muscle precedes dissolution of collagen (33.34). Data are not 
available in humans on the relation between left ventricular 
mass regrusiun and collagen content after treatment of 
arwinl hypertension. However, regression of left ventricu- 
Idr rnahs in spontaneously hypertensive rats treated with 
nifcdapine is accumpamed by a reduction in collagen content 
(27). In these rats. the muxlelcollagen ratio is unchanged 
atler left ventncular nnss repression and there is no increase 
in myocardial stiffness. 
K6ti al treatment on catecholsmines and plasma rain 
activity. Over the year. there was no detectable activation of 
either the sympathetic or the rain system in patients who 
were on extended release nifedipine monotherapy. The 
ruble catecholamine level is probably a reflection of the 
pharmacologic profile of this agent. which has a relatively 
cunatant plnsms level over 24 h (191. This leads to relatively 
minur Auctuatiuns in blood pressure and hence lirtle or no 
reflex sympathetic activation. Calcium channel antagonists 
in general have little &ect an plasma renin activity. In 
comia~t. as is typically seen. those patients who required 
chlorthalidunc had a trend toward an increase in plasma 
renin activity and norepinephrine concentration 
Alrirrl nulrirrrric pephk has been shown to Libit rain 
wretiun aI possibly sympnhetic system activation 
(35.36). The observed marked decrease in atrial natriureric 
pcptide might have led to an increase in these two vnsopres- 
sor ayshms. Thib did not occur in patients treated wbh 
wended releax nifedipine monotherapy. as evidenced by 
the lack of increase in plasma renin activity. norepinephrine 
and hart rate during the course of the study. Thus. there 
was nu neuroendocrine aciivation to offset the reduction in 
atrial natriuretic peptide ad treatment with extended re- 
Isa% nifedipine. In contrast. treatmen! of hypertension with 
vraodilntors. such 8s hydralazine and minoxidil, leads to 
acliwtion of the rain and sympathetic systems 137). 
E&t of lreatment on airial sslriuretic peptide. The re- 
duction in atrial natriuretic peptide that occurred wtth the 
treatment is important because the most likely ewplanation 
for this finding is an improvement in cardiac filling pressures 
(38). Atriai natriuretic peptide is secreted by the atria under 
conditions of increased atrial stretch (391. Althou& arrial 
natriuretic peptide is not elevated in all hypertensive pa- 
tients. it appears to be elevated in severe hypertenston i4Ul. 
where cardiac hllmg pressures might increase as a result of 
elevated left ventricularafterload (II J. In thi5 setting. release 
of atria1 natriuretic peptide might be protective because of ns 
renal and systemic actions in reducing intravascular volume. 
With sustained cmtrol of arterial prersure. as occurred in 
this study, cardiac ftlling pressures and hence the stimulus 
for release of airial natriuretic peptide would be dimintshed. 
This hypothesis is sapported by the finding that untreated 
patients with moderate or severe hypenennon demonstrate 
a marked decrease in left atria1 filling pressure after ireat- 
ment with nicardipine. another dihydropyrtdine calcium 
channel blocker (41). 
Unlikely mechnisms /br rkv red~iioa in orrid rwrri- 
urdc pepfide are direct inhibition by nifedipine on atrial 
secretion of this hormone or its reduced synthesis by the 
ventricle. Several studies (42-441 have shown that short- 
term administration of calcium channel blockers either in- 
creases or has no effect on atrial natriureiic prptidc be:rc- 
tion. Finally. the normal concentration of atrial natriuretic 
pptide in the ventricle is at least 3Wfold lower than thP in 
the atrium (39.451. and even in stales of ventricular hypcr- 
trophy, the amount of alrial natriurelic peptidc mesbenger 
ribonucleic acid found in ventricular tissue is significantly 
lower than that in atria! tissue (46). Therefore. it is unlikely 
that decreased ventricular production would accoum for the 
markeddecreasc in atria1 natriuretic peptide observed in thtx 
study. 
Clinical impiiitions. Untreated scwrc hypenensiol: is 
associated with significant cardiovascular morbidity and 
mortality within IS months of delecrion I61 and e<hocmdin 
graphic evidence of I& ventricular hypetrrophy imptrts an 
additional risk (2.47). Blood pressure control in hevere 
hypertension has usually required multlplc drug therapy with 
diuretic agents. peripheral adrenergic bluckers and cawdi- 
laton (48). with their attcndunt side effect\. cost and dl- 
culty in achieving patient compliance. This study demon- 
&ales that left venlricular mahs regresrian accompames 
sustained blood pressure reduction in pulientr with sercre 
hyoenension treated with extended release nifcdipine. Fur- 
thermore. this therapy is araociatcd uith favorable effects on 
left ventricular performance and atrial natriuretic peptidc. 
with a highly acceptAle ride eficct prohlc. 
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